)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
IN8bio
IN8bio (INAB) investor relations material
IN8bio Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Cash of $14.0M at September 30, 2026 is expected to fund operations through April 2027; continued development and planned milestones depend on securing additional capital.
Appointed Oxana Polyakova, Ph.D., as SVP of R&D in September; she brings 20 years of experience in gamma-delta T-cell biology and biologics development.
Financial highlights
Q3 operating expenses were $4.721M vs. $3.967M YoY; R&D was $2.599M vs. $2.104M and G&A was $2.122M vs. $1.863M.
Q3 net loss was $4.592M vs. $3.854M; nine-month net loss was $14.463M vs. $14.498M, on operating expenses of $14.922M vs. $14.828M.
Nine-month R&D was $7.705M vs. $7.563M; higher TCE preclinical and personnel costs were largely offset by lower INB-400 clinical and facility costs.
Nine-month G&A was $7.217M vs. $7.265M, primarily reflecting lower personnel-related costs, including stock-based compensation, and reduced professional services.
Outlook and guidance
Initial in vivo data for INB-619 are expected by year-end 2026; timing and planned milestones are contingent on a successful additional capital raise.
INB-100 expansion-cohort treatment is expected to finish with a clinical update at ASH in December 2026; further INB-400 overall-survival follow-up is expected at SNO in November 2026.
Forward-looking milestones include preclinical and clinical data readouts, patient dosing timelines, and FDA guidance on regulatory pathways for the DeltEx DRI GBM program.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IN8bio
- Gamma-delta T-cell programs advance toward fall animal data and FDA path guidance.INAB
Small-Cap Virtual Conference - Gamma delta T cell platforms advance with strong efficacy, safety, and regulatory momentum.INABH.C. Wainwright 28th Annual Global Investment Conference
- Advancing gamma-delta T cell therapies with strong data and key milestones ahead in 2026.INABCorporate presentation
- Net loss narrowed to $4.8M in Q2 2026; DeltEx DRI in GBM achieved >19.5 months mOS.INABQ2 2026
- γδ T cell therapies show strong efficacy and safety in cancer and autoimmune trials, with key 2026 milestones ahead.INABCorporate presentation
- Repeat dosing of gamma-delta T cell therapies yields strong survival and immune benefits in GBM.INABR&D Day 2026
- Biopharma innovator targets $200M shelf offering for cell therapy pipeline amid going concern risk.INABRegistration filing
- Net loss narrowed to $5.1M in Q1 2026; strong GBM data and limited cash runway.INABQ1 2026
- Gamma delta T cell therapies and novel engagers show strong efficacy and safety, with major milestones ahead.INABBiotech Resurgence: Platforms and Pipelines of Today's Innovators
Next IN8bio earnings date
Q4 202612 Mar, 2027
IN8bio
Next IN8bio earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
IN8bio Inc., previously known as Incysus Therapeutics, is a clinical-stage biopharmaceutical company focused on the development of innovative gamma-delta T cell therapies for cancer treatment. Their portfolio includes lead product candidates in various phases of clinical trials, targeting conditions such as glioblastoma and acute leukemia, alongside a broad spectrum of preclinical programs aimed at solid tumors. Utilizing their proprietary DeltEx platform, IN8bio develops both autologous and allogeneic gamma-delta T cell therapies, leveraging the unique properties of gamma-delta T cells to differentiate between healthy and diseased tissues. The company was established in 2016 and is headquartered in New York, New York, with its primary scientific operations based in Birmingham, Alabama. Its shares are listed on the NASDAQ.